- Home
- Publications
- Publication Search
- Publication Details
Title
Chemoresistance in Pancreatic Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 18, Pages 4504
Publisher
MDPI AG
Online
2019-09-11
DOI
10.3390/ijms20184504
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition
- (2019) Maher Y. Abdalla et al. Translational Research
- Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition
- (2019) Rita Lawlor et al. Cancers
- SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)
- (2019) Jing Luan et al. JOURNAL OF DRUG TARGETING
- Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
- (2019) Junko Murai et al. PHARMACOLOGY & THERAPEUTICS
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer
- (2019) Janet E. Murphy et al. JAMA Oncology
- Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
- (2019) Sara Pusceddu et al. Cancers
- Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer
- (2019) Man Li et al. JOURNAL OF CONTROLLED RELEASE
- Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
- (2019) Awa Sarr et al. Scientific Reports
- miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis
- (2019) Madurantakam Royam et al. Cancers
- Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer
- (2018) Talar Tatarian et al. ANNALS OF SURGERY
- nab -Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
- (2018) Rosemary Young et al. Asia-Pacific Journal of Clinical Oncology
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
- (2018) N. O. Elander et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
- (2018) Daoxiang Zhang et al. CANCER RESEARCH
- MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy
- (2018) Limin Huang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11)Expression with Class I Histone Deacetylase Inhibitors
- (2018) Sai-Wen Tang et al. CLINICAL CANCER RESEARCH
- miR-196a Is Able to Restore the Aggressive Phenotype of Annexin A1 Knock-Out in Pancreatic Cancer Cells by CRISPR/Cas9 Genome Editing
- (2018) Raffaella Belvedere et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2018) Guangbing Xiong et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review
- (2018) Ezzeddine Chouat et al. PANCREATOLOGY
- EMT: Mechanisms and therapeutic implications
- (2018) Mohini Singh et al. PHARMACOLOGY & THERAPEUTICS
- Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
- (2018) Sarah P. Blagden et al. BRITISH JOURNAL OF CANCER
- Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
- (2018) Etienne Giroux-Leprieur et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
- (2018) Zhongyi Guo et al. International Journal of Nanomedicine
- Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
- (2018) Jie Cao et al. Molecular Cancer
- TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1
- (2018) Guillem Lambies et al. CANCER RESEARCH
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells
- (2018) Ita Novita Sari et al. Cells
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis
- (2017) Q. L. Han et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- The role of stromal cancer-associated fibroblasts in pancreatic cancer
- (2017) Dagny von Ahrens et al. Journal of Hematology & Oncology
- Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
- (2017) Julia Joung et al. Nature Protocols
- Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial)
- (2017) Ken-ichi Okada et al. ONCOLOGY
- Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy
- (2017) Marek Sierzega et al. PANCREAS
- Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
- (2017) Patricia Dauer et al. PANCREATOLOGY
- Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine
- (2017) Toru Aoyama et al. Oncology Letters
- Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
- (2017) Ali McBride et al. Expert Review of Clinical Pharmacology
- A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study
- (2016) Sukhwinder Kaur et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis
- (2016) Chenggang Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer
- (2016) Pei Fan et al. CANCER LETTERS
- GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer
- (2016) Jiangning Gu et al. CANCER LETTERS
- Key role of pancreatic stellate cells in pancreatic cancer
- (2016) Srinivasa P. Pothula et al. CANCER LETTERS
- Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
- (2016) Lucy Ireland et al. CANCER RESEARCH
- Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
- (2016) A. Orlandi et al. Clinical & Translational Oncology
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- Equilibrative nucleoside transporters—A review
- (2016) Rebba C. Boswell-Casteel et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer
- (2016) Yang Liu et al. TUMOR BIOLOGY
- Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer
- (2016) XUEFEI TIAN et al. Oncology Letters
- Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice
- (2016) Roman Maresch et al. Nature Communications
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
- (2015) Jacob Elebro et al. ACTA ONCOLOGICA
- Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study
- (2015) Knut J. Labori et al. ACTA ONCOLOGICA
- The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival
- (2015) Daniel Delitto et al. BMC CANCER
- Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer
- (2015) J A Galván et al. BRITISH JOURNAL OF CANCER
- A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
- (2015) B. Venugopal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance
- (2015) C. Duluc et al. EMBO Molecular Medicine
- Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma
- (2015) Ilona Kohler et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2
- (2015) Takuya Shimada et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
- (2015) Kentaro Minami et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment
- (2015) Ken Ohmine et al. MOLECULAR PHARMACEUTICS
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
- (2015) Xiaofeng Zheng et al. NATURE
- Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
- (2015) Silvana Konermann et al. NATURE
- miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer
- (2015) ZHI-GUO REN et al. ONCOLOGY REPORTS
- HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer
- (2015) FENG CAO et al. ONCOLOGY REPORTS
- Pancreatic cancer: The microenvironment needs attention too!
- (2015) M.V. Apte et al. PANCREATOLOGY
- The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2
- (2015) Nicolas Skrypek et al. Oncotarget
- Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
- (2015) Hui Zhang et al. Oncotarget
- Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
- (2015) Vanesa Nogales et al. Oncotarget
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer
- (2014) Florencia McAllister et al. CANCER BIOLOGY & THERAPY
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response
- (2014) Alexandre Maréchal et al. CELL RESEARCH
- Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
- (2014) Magdalena Slusarczyk et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets
- (2014) Corynn Kasap et al. Nature Chemical Biology
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
- (2014) CONGFEI WANG et al. ONCOLOGY REPORTS
- A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
- (2014) D. Li et al. PANCREATOLOGY
- hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
- (2014) Stina Nordh WORLD JOURNAL OF GASTROENTEROLOGY
- The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
- (2013) Beatrice Mohelnikova-Duchonova et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
- (2013) F. E. Stuurman et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner
- (2013) S Pérez-Torras et al. Cell Death & Disease
- DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
- (2012) Yuriko Saiki et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Early diagnosis of pancreatic cancer: challenges and new developments
- (2012) Sukhwinder Kaur et al. Biomarkers in Medicine
- Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance
- (2012) FENG-TING HUANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
- (2012) N Skrypek et al. ONCOGENE
- CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells
- (2011) Y. D. Bhutia et al. CANCER RESEARCH
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression
- (2011) Guo ONCOLOGY REPORTS
- Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
- (2010) Andries M. Bergman et al. INVESTIGATIONAL NEW DRUGS
- The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
- (2009) C. L. Costantino et al. CANCER RESEARCH
- Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
- (2009) T. Arumugam et al. CANCER RESEARCH
- Role of microRNA in anticancer drug resistance
- (2009) Tongsen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
- (2009) Funamizu ONCOLOGY REPORTS
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
- (2009) Suzie J. Scales et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
- (2008) J. M. Bailey et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now